Abstract： Prostate cancer(PCa)is a malignant reproductive disease that afflicts men worldwide,with a favourable response to androgen deprivation therapy(ADT)in the initial stages of the disease.However,patients inevitably develop hormonal resistance,which progresses to castrate-resistant prostate cancer(CRPC)and greatly reduces patient survival.Clinical studies of CRPC are mainly centred around the androgen receptor(AR),but AR bypass pathways also exist.Therefore,this review discussed the formation mechanism of CRPC and the progress of immunotherapeutic regimens for patients with CRPC,focusing on both androgen receptor-dependent and bypass pathways.